**Supplementary Table 2. Summary of antibody GMRs of pre-booster:13m**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Group** | **Anti-PT GMR (95% CI)** | **Anti-FHA GMR (95% CI)** | **Anti-FIM GMR (95% CI)** | **Anti-PRN GMR (95% CI)** | **Anti-DT GMR (95% CI)** | **Anti-TT GMR (95% CI)** |
| **BOOSTRIX-IPV®** | 0.21 (0.15-0.29) | 0.86 (0.5-1.48) | 0.69 (0.41-1.17) | 0.66 (0.42-1.06) | 0.07 (0.06-0.1) | 0.07 (0.05-0.11) |
| **REPEVAX®** | 0.25 (0.15-0.44) | 0.54 (0.21-1.4) | 0.99 (0.62-1.6) | 0.39 (0.16-0.93) | 0.08 (0.06-0.12) | 0.05 (0.04-0.07) |
| **CONTROL** | 0.52 (0.24-1.13) | 0.85 (0.35-2.07) | 1.52 (0.88-2.62) | 0.51 (0.24-1.08) | 0.09 (0.07-0.11) | 0.05 (0.03-0.07) |
| **ALL** | 0.28 (0.21-0.39) | 0.73 (0.47-1.15) | 0.97 (0.72-1.32) | 0.51 (0.34-0.77) | 0.08 (0.07-0.1) | 0.06 (0.05-0.07) |

Table summarising antigen-specific IgG GMRs to compare the IgG GMCs at 13 months of age and at pre-booster, in children whose mothers received one of two antenatal pertussis-containing vaccines or not.